Tumor-Targeted Salmonella typhimurium Overexpressing Cytosine Deaminase: A Novel, Tumor-Selective Therapy

  • Ivan KingEmail author
  • Martina Itterson
  • David Bermudes
Part of the Methods in Molecular Biology™ book series (MIMB, volume 542)


The ideal anticancer regimen is one that is specific for cancer cells with limited toxicity to normal tissues. Genetically modified, nonpathogenic Salmonella offer a potential way to induce direct tumoricidal activity or to deliver tumoricidal agents to tumors. An attenuated strain of Salmonella typhimurium, called VNP20009, and its derivative TAPET-CD (which expresses Escherichia coli cytosine deaminase) are highly selective for tumor tissue and can deliver therapeutic proteins preferentially to tumors in preclinical models. Both VNP20009 and TAPET-CD have been investigated successfully in Phase 1 clinical trials in cancer patients.

Key Words

cytosine deaminase 5-fluorocytosine 5-fluorouracil Salmonella TAPET-CD tumor VNP20009 



The authors thank Brooks Low, Samuel Miller, and John Pawelek for helpful suggestions and Kimberly Troy, Jeremy Pike, and Caroline Clairmont for technical assistance. This work was supported by Vion Pharmaceuticals, New Haven, CT.


  1. 1.
    Pawelek, J.M., Low, K.B., and Bermudes, D. (1997) Tumor-targeted Salmonella as a novel anticancer vector. Cancer Res. 57, 4537–4544.PubMedGoogle Scholar
  2. 2.
    Bermudes, D., Low, B., and Pawelek, J. (2000) Tumor-targeted Salmonella: Highly selective delivery vectors. Adv. Exp. Med. Biol. 465, 57–63.PubMedCrossRefGoogle Scholar
  3. 3.
    Murray, S. R., Suwwan de Felipe, K., Obuchowski, P. L., Pike, J., Bermudes, D. and Low, K. B. (2004) Hot spot for a large deletion in the 18- to 19-centisome region confers a multiple phenotype in Salmonella enterica Serovar Typhimurium strain ATCC 14028. J Bacteriol. 186, 8516–8523.PubMedCrossRefGoogle Scholar
  4. 4.
    Zheng, L., Luo, X., Feng, M., Li, Z., Le, T., Ittensohn, M. et al. (2000) Tumor amplified protein expression therapy: Salmonella as a tumor-selective protein delivery vector. Oncology Res. 12, 127–135.Google Scholar
  5. 5.
    Bermudes, D., Zheng, L., and King, I. C. (2002) Live bacteria as anticancer agents and tumor-selective protein delivery vectors. Curr Opin Drug Discover Develop. 5, 194–199.Google Scholar
  6. 6.
    Bermudes, D., Low, K.B., Pawelek, J., Feng, M., Belcourt, M., Zheng, L., and King, I. (2001) Tumor-selective Salmonella-based cancer therapy. Biotechnol. Genet. Eng. Rev. 18, 219–233.PubMedGoogle Scholar
  7. 7.
    Dubois, L., Dresselaers, T., Landuyt, W., Paesmans, K., Mengesha, A., Wouters, B.G., et al. (2007) Brit. J. Cancer 96, 758–761.PubMedCrossRefGoogle Scholar
  8. 8.
    King, I., Bermudes, D., Lin, S., Belcourt, M., Pike, J., Troy, K., et al. Tumor-targeted Salmonella expressing cytosine deaminase as an anticancer agent. Human Gene Therapy 13, 1225–1233.Google Scholar
  9. 9.
    Toso, J.F., Gill, V.J., Hwu, P., Marincola, F.M., Restifo, N.P., Schwartzentruber, D.J., et al. (2002) Phase I study of the intravenous administration of attenuated Salmonella typhimurium to patients with metastatic melanoma. J Clinical Oncol. 20, 142–152.CrossRefGoogle Scholar
  10. 10.
    Nemunaitis, J., Cunningham, C., Senzer, N., Kuhn, J., Cramm, J., Litz, C., et al. (2003) Pilot trial of genetically modified, attentuated Salmonella expressing the E. coli cytosine deaminase gene in refractory cancer patients. Cancer Gene Therapy 10, 737–744.PubMedCrossRefGoogle Scholar
  11. 11.
    Low, K.B., Ittensohn, M., Le, T., Platt, J., Sodi, S., Amoss, M., et al. (1999) Lipid A mutant Salmonella with suppressed virulence and TNFα induction retain tumor-targeting in vivo. Nature Biotechnol. 17, 37–41.Google Scholar
  12. 12.
    Davis, R. W., Botstein, D., and Roth, J. R. (1980) Advanced Bacterial Genetics. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York.Google Scholar
  13. 13.
    Low, K.B., Ittensohn, M., Luo, X., Zheng, L., King, I., Pawelek, J.M., et al. (2003) Construction of VNP20009. Methods in Molecular Med. 90, 47–59.Google Scholar
  14. 14.
    Sambrook, J., Fritsch, E.F., and Maniatis, T. (1989) Molecular Cloning: A Laboratory Manual, 2nd Ed., Cold Spring Harbor Press, Cold Spring Harbor, NY.Google Scholar
  15. 15.
    Austin, E. A. and Huber, B. E. (1993) A first step in the development of gene therapy for colorectal carcinoma: cloning, sequencing and expression of Escherichia coli cytosine deaminase. Molecular Pharmacol. 43, 380–387.Google Scholar
  16. 16.
    Donnenberg, M. S. and Kaper, J. B. (1991) Construction of an eae deletion mutant of enteropathogenic Escherichia coli by using a positive-selection suicide vector. Infection and Immunity 59, 4310–4317.PubMedGoogle Scholar
  17. 17.
    Hanahan, D. (1983) Studies on transformation of Escherichia coli with plasmids. J. Mol. Biol. 166, 557–580.PubMedCrossRefGoogle Scholar

Copyright information

© Humana Press, a part of Springer Science+Business Media, LLC 2009

Authors and Affiliations

  1. 1.Vion Pharmaceuticals, Inc.New HavenUSA
  2. 2.Celator Pharmaceuticals Corp.VancouverCanada

Personalised recommendations